Clinical Effect Analysis of Different Doses of Creatine Phosphate Sodium Combined with Immunoglobulin in the Treatment of Pediatric Viral Myocarditis
Wang M, Deng J, Xing S, Li L
Pediatric cardiology · 2 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Tianjin Key Medical Discipline (Specialty) Construction Project
Según 1 financiador declarado.
Publicación
- Publicado
- 2024-03-20 · Pediatr Cardiol · vol. 45 · número 5 · págs. 1048–1054
- Editorial
- Springer Science+Business Media
- Citado
- 2 citas · más que el 68% de estudios similares · 0.5× el promedio de su campo
- Referencias
- 31 trabajos
- Acceso
- De pago
- Áreas de investigación
- Viral Infections and Immunology Research · Kawasaki Disease and Coronary Complications · Streptococcal Infections and Treatments
- Palabras clave
- immunoglobulin therapy, combination therapy, cardiac function, inflammatory cytokines, immune function, adverse drug reactions, dose comparison
- MeSH
- humans, virus diseases, myocarditis, phosphocreatine, immunoglobulins, treatment outcome, drug therapy, combination, dose-response relationship, drug, child, child, preschool, female, male
4 autores
- Meng Wang🇨🇳 · autor de correspondenciaTianjin University; Tianjin Children's Hospital
- Jiegang Deng🇨🇳Tianjin University; Tianjin Children's Hospital
- Shuhua Xing🇨🇳Tianjin University; Tianjin Children's Hospital
- Lu Li🇨🇳Tianjin University; Tianjin Children's Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
The purpose of this paper was to unravel the clinical effect analysis of different doses of creatine phosphate sodium (CPS) combined with immunoglobulin in the treatment of pediatric viral myocarditis (VMC). One hundred and twenty children with VMC were recruited and randomized into three groups (40 patients each). Group I received 1.0 g of CPS dissolved in 100 mL of 5% glucose injection intravenously 1 time/day; group II received 1.25 g of CPS dissolved in 125 mL of 5% glucose injection intravenously 1 time/day; group III received 1.5 g of CPS dissolved in 150 mL of 5% glucose injection intravenously 1 time/day; then all three groups were treated with combined use of immunoglobulin (300-400 mg/day) intravenously once a day; and all three groups were treated for 14 days. The clinical efficacy, cardiac function, serum inflammatory factor levels, immune function, and the occurrence of drug toxicity and adverse effects of the children in the three groups were compared after 14 days of treatment. All three groups achieved better therapeutic effects after treatment, in which the effective rate of the Group II and Group III was notably higher versus the Group I. Lower levels of cTnI, CK-MB, LDH, AST, IL-18, IL-6, IFN-γ, and LVEDD and higher CD3+, CD4+, and CD4+/CD8+, FS, and LVEF values were noted in the Group II and Group III versus the Group I, and the results were more pronounced in the high-dose group. The liver and kidney functions of the children in the three groups before and after treatment did not show any significant changes and the incidence of adverse reactions during the treatment period was low in all three groups. Children with VMC can be treated with high-dose CPS in combination with immunoglobulin, which can improve their cardiac function and immune function and reduce the inflammatory response with good overall therapeutic efficacy and fewer adverse effects.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.